Work

Prognostic Value of Immunohistochemical Markers in High-risk Non-muscle Invasive Bladder Cancer

Year: 2025

Type: article

Abstract: Non-muscle invasive bladder cancer (NMIBC) accounts for nearly 75% of all bladder cancer cases. Despite appropriate transurethral resection of bladder tumor (TURBT) and adjuvant intravesical therapy, recurrence occurs in 50–70% of patients, and progression to muscle-invasive disease develops in 10–20%. Standard clinical prognostic factors (tumor stage, grade, multiplicity) do not fully explain the variability in outcomes. Therefore, identifying reliable molecular and morphological markers is crucial for improving patient risk stratification and developing individualized treatment strategies.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.17233269

Authors: Komiljonov, K.D., Allamova, Sh.M., Shukurov, M.Kh.

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7083813259

FWCI:

Cites:

Cited by:

Related to: